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Abstract 
Background: Streptococcus suis serotype 2 is a major swine pathogen and zoonotic agent worldwide causing mainly 
meningitis and septicemia. Hyaluronate lyases are enzymes that degrade hyaluronic acid, a major constituent of ani-
mal tissues, and have been reported as virulence factors in various bacterial species. Since the hyaluronate lyase of S. 
suis has been considered ambiguously as a virulence factor, we screened 50 isolates from the three major clonal com-
plexes found in North America (sequence type [ST] 1, ST25, and ST28) known to differ in their degree of virulence in 
order to link the presence or absence of this activity with the degree of virulence. Moreover, the effect of exogenous 
hyaluronic acid on S. suis virulence factor gene expression and the pro-inflammatory response of brain macrovascular 
endothelial cells (BMEC) was also investigated.
Results: We found that all but one ST1 isolates (high virulence) were devoid of hyaluronate lyase activity whereas all 
ST25 (intermediate virulence) and ST28 (low virulence) isolates possessed the activity. A 2 bp insertion was respon-
sible for the lack of activity in ST1 strains. Since the most virulent isolates did not degrade hyaluronic acid, this tissue 
component may be found during the infectious process. Therefore, we investigated its effect on S. suis and host cells. 
Hyaluronic acid was found to modulate S. suis adhesion to BMEC, to increase S. suis virulence factor expression, and to 
enhance pro-inflammatory cytokine secretion by BMEC.
Conclusions: These findings suggest that S. suis hyaluronate lyase does not represent a critical virulence factor in 
its active form. However, exogenous hyaluronic acid that is likely to interact with S. suis and host cells during the 
course of infection appears to modulate several virulence determinants of the bacterium, in addition to promote 
inflammation.
Keywords: Adherence, Cytokines, Hyaluronate lyase, Hyaluronic acid, Streptococcus suis
© 2015 Haas et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Streptococcus suis is an important swine pathogen world-
wide responsible for substantial economic losses in the 
swine industry. Among the 29 known serotypes deter-
mined by the capsular antigenic composition, serotype 2 
is predominant in swine infections, causing meningitis, 
pneumonia, septicemia, endocarditis and arthritis [1–3]. 
Moreover, S. suis is regarded as an emerging zoonotic 
agent, mostly in Asia, since it can infect humans in close 
contact with contaminated pigs or their byproducts. The 
general population in Asia is also at risk due to consump-
tion of raw pork meat or blood [4]. Two S. suis outbreaks 
were reported in China in 1998 and 2005 that caused over 
60 deaths [5]. S. suis is also the major cause of adult men-
ingitis in Vietnam [6]. S. suis serotype 2 has been divided 
into clonal complexes composed of sequence types (STs) 
determined by multilocus sequence typing (MLST) [7]. 
Open Access
*Correspondence:  daniel.grenier@greb.ulaval.ca 
1 Groupe de Recherche en Écologie Buccale (GREB), Faculté de Médecine 
Dentaire, Université Laval, 2420 Rue de la Terrasse, Quebec City, QC G1V 
0A6, Canada
Full list of author information is available at the end of the article
Page 2 of 11Haas et al. BMC Res Notes  (2015) 8:722 
Two dominant (ST25 and ST28) and one less frequent 
(ST1) STs were identified in North America, which differ 
in their virulence in a mouse infection model [8]. Strains 
belonging to ST1 are highly virulent whereas ST25 and 
ST28 isolates have an intermediate and low virulence, 
respectively.
To date, several virulence factors have been identified 
or proposed in S. suis [9, 10]. The sialic-acid rich capsule 
is considered one of the most important virulence factors 
since acapsular mutants of S. suis were more susceptible 
to phagocytosis by macrophages and avirulent in animal 
models (piglet and mouse) [11, 12]. Additional virulence-
associated markers such as suilysin [13], extracellular fac-
tor [14], muraminidase-released protein [14], proteases 
[15, 16], and cell-wall anchored DNase [17] may also con-
tribute to S. suis pathogenesis.
In 2004, Allen et al. identified a hyaluronate lyase pro-
duced by S. suis (serotype 7) [18]. Hyaluronate lyases 
degrade hyaluronic acid, a major constituent of the 
extracellular matrix [19] made of repeating disaccha-
ride units of β-1,4-D-glucuronic acid-β-1,3-N-acetyl-β-
d-glucosamine, by β-elimination at the β-1,4 glycosidic 
linkages leading to Δ 4,5-unsaturated oligosaccharides 
[20]. Hyaluronate lyases produced by streptococci can 
play important roles in pathogenesis, from providing 
nutrients to the bacterium to enhancing the pathogen’s 
spread into host tissues by degrading hyaluronic acid 
[21]. More specifically, the hyaluronate lyase produced 
by Streptococcus intermedius has been shown to contrib-
ute to bacterial detachment from biofilms, consequently 
enhancing its dissemination in the host [22]. Evidence 
have been brought that Streptococcus agalactiae hyalu-
ronate lyase is involved in macrophage intracellular sur-
vival as well as regulation of pro-inflammatory cytokine 
expression [23]. The hyaluronate lyase produced by S. 
suis has been suggested as a virulence factor, although 
no direct link could be established by studying the dis-
tribution of active hyaluronate lyase among S. suis field 
strains. This latter study also showed that a number of 
strains of S. suis can display an inactive form of hyaluro-
nate lyase due to a 2 bp insertion causing a shifted read-
ing frame resulting in a truncated and inactive form of 
the protein [24]. A role assigned to S. suis hyaluronate 
lyase relates to degradation of hyaluronic acid generating 
oligosaccharides that were then processed by the bac-
terium as a carbon source [18]. A role of S. suis hyalu-
ronate lyase in the pathogenesis of meningitis has been 
recently proposed by Wu et al. since the protein was able 
to interact with an angiogenin inhibitor, a property that 
may lead to an increased permeability of the blood brain 
barrier [25].
In group A streptococci (GAS), also known as Strepto-
coccus pyogenes, the hyaluronate lyase has been shown 
to contribute to subcutaneous spread and growth of the 
pathogen [26]. However, in a more recent study, the GAS 
hyaluronate lyase has been found to be present in an 
inactive form in the most virulent strains [27]. Given the 
fact that GAS capsule is mainly constituted of hyaluronic 
acid, expression of a functional hyaluronate lyase may 
cause capsule degradation and therefore increase sus-
ceptibility of the pathogen to the host immune system. 
Consequently, Hynes et al. suggested that GAS hyaluro-
nate lyase should be considered as an anti-virulence fac-
tor [27]. S. suis is also known to express a capsule [9, 10]. 
However, its major constituent is sialic acid rather than 
hyaluronic acid as for S. pyogenes [27].
In the first part of this study, we investigated the distri-
bution and genetic diversity of S. suis hyaluronate lyase 
among the three major STs of S. suis serotype 2 found in 
North America (ST1, ST25, ST28) that are known to differ 
in their degree of virulence, in order to provide an insight 
on the involvement of this protein in S. suis virulence. In 
the second part of the study, various aspects of the interac-
tion between exogenous hyaluronic acid and S. suis were 
analyzed, including the effect on biofilm formation, adher-
ence to brain microvascular endothelial cells (BMEC) and 
virulence factor gene expression. Lastly, since it has been 
shown that hyaluronic acid can regulate inflammation in 
host cells [28], we studied the effect of hyaluronic acid on 
pro-inflammatory cytokine secretion by BMEC.
Methods
Bacterial strains and culture conditions
Strains of S. suis serotype 2 used in this study as well as 
their corresponding ST and origin are listed in Table  1. 
Bacteria were routinely grown in Todd-Hewitt Broth 
(THB; BD-Canada, Mississauga, ON, Canada) at 37  °C 
unless specified otherwise.
Plate assay for hyaluronate lyase activity
Hyaluronate lyase activity was determined using the plate 
assay previously described by Smith and Willett [29]. 
Briefly, 10 µl of overnight cultures of S. suis were spotted 
on Brain Heart Infusion (BHI; BD-Canada) agar plates 
supplemented with 0.04 % (w/v) hyaluronic acid (Sigma-
Aldrich Canada Co., Oakville, ON, Canada) and 1 % (w/v) 
bovine serum albumin (BSA). Plates were then incubated 
for 24 h at 37 °C. Hyaluronate lyase activity was revealed 
by the addition of 2 M acetic acid for 3 min which allows 
precipitation of the complex BSA/hyaluronic acid, the 
presence of a clear halo around bacterial growth area was 
indicative of hyaluronate lyase activity (Fig. 1).
Gene amplification and sequencing
In order to compare DNA sequences of the entire hya-
luronate lyase gene found in S. suis serotype 2 strains 
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Table 1 Sequence type, origin, type of infection, and hyaluronate lyase activity of S. suis serotype 2 isolates
Strain Sequence type Origin Type of infection Hyaluronate lyase activity
P156/00P6 1 Argentina Unknown −
P477/03P1 1 Argentina Meningitis −
P517/03P4 1 Argentina Meningitis −
P613/05P3 1 Argentina Unknown −
Prot 611/07 1 Argentina Unknown −
31533 1 France Meningitis −
DAT229 1 Japan Endocarditis −
DAT261 1 Japan Pneumonia −
DAT264 1 Japan Meningitis −
NIAH1143 1 Japan Meningitis −
MNCM01 1 Thailand Endocarditis −
MNCM06 1 Thailand Meningitis −
MNCM16 1 Thailand Meningitis −
S735 1 The Netherlands Unknown +
P1/7 1 United Kingdom Meningitis −
MGGUS2 1 USA Meningitis −
MGGUS3 1 USA Meningitis −
1043248 25 Canada Meningitis +
1043629 25 Canada Pneumonia +
1044423 25 Canada Unknown +
1053253 25 Canada Pneumonia +
1085543 25 Canada Meningitis +
1102337 25 Canada Meningitis +
1102864 25 Canada Septicemia +
LPH4 25 Thailand Septicemia +
LPH12 25 Thailand Septic shock +
MNCM04 25 Thailand Meningitis +
MNCM10 25 Thailand Septicemia +
MNCM24 25 Thailand Endocarditis +
MNCM26 25 Thailand Endocarditis +
MNCM51 25 Thailand Septicemia +
MGGUS4 25 USA Meningitis +
MGGUS5 25 USA Unknown +
1054471 28 Canada Meningitis +
1057906 28 Canada Meningitis +
1084708 28 Canada Unknown +
1088563 28 Canada Meningitis +
1097205 28 Canada Meningitis +
90-1330 28 Canada Healthy pig +
DAT242 28 Japan Meningitis +
DAT245 28 Japan Meningitis +
DAT246 28 Japan Septicemia +
DAT251 28 Japan Unknown +
DAT292 28 Japan Unknown +
MNCM43 28 Thailand Endocarditis +
MGGUS9 28 USA Endocarditis +
MGGUS10 28 USA Pneumonia +
MGGUS11 28 USA Pneumonia +
MGGUS12 28 USA Pneumonia +
MGGUS13 28 USA Meningitis +
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belonging to different STs, amplification of overlap-
ping fragments was performed by PCR using primers 
designed with Primer3Plus [30] and listed in Table  2. 
Amplicons were then sequenced, the full hylA genes 
were assembled and then compared to the hyaluro-
nate lyase gene previously identified in S. suis serotype 
7 (accession number AJ3088328) [18] using BioEdit 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html) and 
the NCBI database (http://blast.ncbi.nlm.nih.gov/Blast.
cgi).
Effect of hyaluronic acid on biofilm formation by S. suis
An overnight culture of S. suis P1/7 (ST1, negative 
for hyaluronate lyase activity) was diluted to an opti-
cal density at 660  nm (OD660) of 0.1 in THB supple-
mented or not with hyaluronic acid (Sigma-Aldrich 
Canada Co.; 0.01–1 mg/ml). Two hundred microliters 
of the bacterial suspension were seeded into wells of a 
96-well tissue culture microplate. After incubation at 
37 °C for 24 h, S. suis growth was monitored by record-
ing the OD660. The medium and planktonic bacteria 
were then aspirated and biofilms were washed three 
times with 50 mM phosphate-buffered saline (PBS; pH 
7.2). Biofilms were then stained with 100 µl of 0.04 % 
crystal violet for 10  min. Three washing steps were 
performed with PBS to remove the excess of dye and 
plates were left to dry for 2  h at 37  °C before adding 
100  µl/well of 95  % ethanol and shaking for 10  min 
to release the stain. The absorbance at 550  nm (A550) 
was then recorded with a xMark microplate spectro-
photometer (Bio-Rad Laboratories, Mississauga, ON, 
Canada).
Effect of hyaluronic acid on adherence of S. suis to BMEC
The human BMEC cell line used in this study has 
been previously described [31]. Cells were grown in 
RPMI 1640 medium (Life Technologies Inc., Burling-
ton, ON, Canada) supplemented with 10 % (v/v) heat-
inactivated fetal bovine serum (Life Technologies Inc.), 
10 % (v/v) Nu-Serum IV supplement (Becton–Dickin-
son Biosciences, Bedford, MA, USA), 2.05 mM l-glu-
tamine, and 1  % penicillin–streptomycin at 37  °C in 
a 5  % CO2 atmosphere. One hundred microliters of 
a BMEC suspension (106 cells/ml) were seeded into 
wells of a 96-well black wall microplate with clear bot-
tom and incubated overnight at 37  °C with 5  % CO2. 
An overnight culture of S. suis P1/7 (ST1, negative for 
hyaluronate lyase activity) was centrifuged at 10,000×g 
for 20  min at 4  °C and washed once in PBS. Bacteria 
were then resuspended in bicarbonate buffer (0.5  M 
NaHCO3, pH 8) to an OD660 = 1, and fluorescein iso-
thiocyanate (FITC) was added to a final concentration 
of 0.03 mg/ml. Labeling of the bacteria was performed 
at 37  °C for 30  min. In the meantime, BMEC were 
washed 3 times with PBS pH 7.2 and 100 µl of culture 
medium supplemented with hyaluronic acid (Sigma-
Aldrich Canada Co.; 0.1, 0.5 and 1 mg/ml) was added. 
Cells were then incubated for 30  min at 37  °C in the 
presence of 5  % CO2. FITC-labelled bacteria were 
washed 3 times with PBS and 100 µl of this suspension 
was added to the BMEC monolayers to a final multi-
plicity of infection (MOI) of 200. The microplate was 
then subjected to a low-speed centrifugation (5 min at 
200×g) to allow contact of bacteria with BMEC, and 
incubated at 37 °C in the presence of 5 % CO2 for 2 h. 
Wells were washed twice with PBS and 200 µl PBS was 
added prior to record fluorescence using a Synergy 2 
microplate reader (BioTek Instruments Inc, Winooski, 
VT, USA) with an excitation wavelength of 485  nm 
and an emission wavelength of 528 nm. Percentage of 
adherence was calculated using the control value (no 
hyaluronic acid) as 100 %.
Fig. 1 Hyaluronate lyase activity of S. suis MGGUS2 (HylA −, left) and 
S. suis S735 (HylA +, right), as determined using the plate assay
Table 2 Primers used for the amplification of hyaluronate 
lyase gene in S. suis strains
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Effect of hyaluronic acid on virulence factor gene 
expression by S. suis
S. suis P1/7 (ST1, negative for hyaluronate lyase activ-
ity) was grown in THB supplemented with hyalu-
ronic acid (Sigma-Aldrich Canada Co.; 0.625, 1.25 and 
2.5 mg/ml) for 6 h in three independent cultures. Total 
RNA was extracted using the RNeasy minikit (Qiagen 
Inc., Mississauga, ON, Canada). The RNA quality was 
controlled using the Experion RNA StdSens Analy-
sis kit (Bio-Rad Laboratories). Purity and quantity of 
the RNA were measured using Nanodrop (Thermo 
Fisher Scientific, Wilmington, DE, USA). Samples 
were then diluted in nuclease-free water to a final 
concentration of 100  ng/µl and cDNA were produced 
using iScript R-T Supermix for RT-qPCR (Bio-Rad 
Laboratories) according to the manufacturer’s pro-
tocol. Gene expression of five putative virulence fac-
tors (capsule [cps2J], muraminidase-released protein 
[mrp], extracellular protein factor [epf], suilysin [sly] 
and cell-wall anchored DNase [ssnA]) was recorded 
using the CFX96 Real-Time System C1000 Thermal 
Cycler (Bio-Rad Laboratories) with the IQ™ SYBR 
Green fluorophore (Bio-Rad Laboratories) according 
to the manufacturer’s protocols, using the 16S rRNA 
as internal control for data normalization as it is rou-
tinely used for gene expression quantification in S. 
suis [32]. Primers, purchased from Life Technologies 
Inc., are listed in Table  3. To validate the specificity 
for each primer pair, melting curves were analyzed and 
migration of PCR products on 1 % agarose gel 45 min 
at 100 V was performed. Amplicons migrated to their 
expected size of 123  bp (16S rRNA), 198  bp (cps2J), 
216  bp (mrp), 162  bp (epf), 97  bp (sly) and 390  bp 
(ssnA) (data not shown).
Effect of hyaluronic acid on secretion of pro‑inflammatory 
cytokines by BMEC
Two ml of a suspension of BMEC (106 cells/ml) in the 
culture medium described above were seeded into each 
well of a 6-well microplate and incubated overnight at 
37  °C in a 5  % CO2 atmosphere. The medium was then 
aspirated and replaced with fresh culture medium sup-
plemented with hyaluronic acid (Sigma-Aldrich Canada 
Co.; 0.1, 0.5, 1, and 2 mg/ml). Hyaluronic acid treatments 
were performed for 24 h at 37 °C prior to collect culture 
supernatants for quantification of interleukin-1β (IL-1β), 
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) 
and interleukin-8 (CXCL8) by enzyme-linked immuno-
sorbent assays (ELISA) (eBioscience Inc., San Diego, CA, 
USA) according to the manufacturer’s instructions.
Statistical analysis
All assays were performed in triplicate and the 
means ± standard deviations were calculated. Differences 
were analyzed for statistical significance using the Stu-
dent’s t test and were considered significant at p < 0.05.
Results
Distribution of hyaluronate lyase activity among S. suis STs
Fifty S. suis serotype 2 strains (17 ST1, 16 ST25, and 17 
ST28) were tested for hyaluronate lyase activity on BHI 
plates supplemented with BSA and hyaluronic acid. 
As shown in Fig.  1, positive hyaluronate lyase activity 
resulted in the formation of a clear halo around the bac-
terial growth. It was found that sixteen out of seventeen 
isolates belonging to ST1, which comprises the most 
virulent strains, were devoid of hyaluronate lyase activity 
(Table 1), whereas all ST25 (intermediate virulence) and 
ST28 (low virulence) isolates possessed the activity. S. 
suis S735 was the only ST1 isolate possessing hyaluronate 
lyase activity.
Comparative analysis of S. suis hyaluronate lyase gene
Given the differences observed in hyaluronate lyase activ-
ity of strains belonging to different STs, the hyaluronate 
lyase gene of nine ST1, three ST25 and three ST28 strains 
was amplified. As we were unable to obtain a proper 
amplification of the full gene due to non-specific ampli-
fication, PCR of overlapping fragments were performed. 
The resulting products were then sequenced and the full 
gene was then assembled for analysis. Comparison of the 
nucleic acid sequences between STs using S. suis sero-
type 7 hylA gene previously described as reference gene 
(accession number AJ3088328) [18] showed the presence 
of four conserved insertions that occurred in ST1 strains 
(Fig. 2): a 21 bp insertion starting at position 192, a 3 bp 
insertion starting at position 330, a 2  bp insertion at 
Table 3 Primers used for  the determination of  virulence 
factor gene expression in S. suis P1/7
Gene Primer sequence (5′–3′) Expected 
amplicon 
size (bp)
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position 1554–1555 and a single bp insertion at position 
2036. Interestingly, the only ST1 strain (S735) that pos-
sessed hyaluronate lyase activity did not display the two 
last insertions in the hyaluronate lyase gene.
Effect of hyaluronic acid on biofilm formation, adherence 
to BMEC, and virulence factor gene expression in S. suis 
P1/7
Given that the above data indicated that the most viru-
lent strains of S. suis (ST1) do not possess hyaluronate 
lyase activity and consequently are likely to interact with 
hyaluronic acid during the course of infection, we then 
investigated the effect of this glycosaminoglycan on bio-
film formation, adherence to BMEC, and virulence factor 
gene expression in S. suis P1/7 (ST1, negative for hyaluro-
nidase activity).
The biofilm assay was performed in a microplate model 
following growth of S. suis in THB supplemented with 
hyaluronic acid, prior to crystal violet staining. Growth 
of S. suis was not affected by the presence of hyaluronic 
acid at concentrations of 0.01–0.1  mg/ml, as determined 
by recording the OD660 following overnight incubation. 
However, in the presence of high concentrations of hyalu-
ronic acid (0.5 and 1 mg/ml), bacterial growth was reduced 
(Fig. 3a). In regard to biofilm formation, no significant effect 
of hyaluronic acid was observed at 0.01 mg/ml, whereas at 
0.05 mg/ml of hyaluronic acid, biofilm formation was sig-
nificantly reduced. Hyaluronic acid at concentrations of 
0.1 and 0.5  mg/ml increased biofilm formation by S. suis 
P1/7. At the highest concentration tested of hyaluronic acid 
(1 mg/ml), biofilm formation by S. suis was attenuated and 
may result from the reduced bacterial growth (Fig. 3b).
To investigate the effect of hyaluronic acid on S. 
suis adherence to BMEC, FITC-labelled bacteria were 
incubated with a monolayer of cells in the presence of 
hyaluronic acid at concentrations ranging between 0.1 and 
1 mg/ml. Adherence of S. suis relative to control (without 
hyaluronic acid) is reported in Fig. 4. An increased adher-
ence (~35 %) was observed in the presence of hyaluronic 
Fig. 2 Comparative analysis of nucleic acid sequence of the hyaluronate lyase gene (hylA) in S. suis belonging to ST1, ST25 and ST28. S. suis serotype 
2 strains belonging to the ST1 group are devoid of hyaluronate lyase activity with the exception of strain S735. Strains belonging to ST25 and ST28 
all possess an active hyaluronate lyase
Fig. 3 Effect of hyaluronic acid on S. suis P1/7 growth (a) and biofilm 
formation (b). *Significantly different from control at p < 0.05
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acid at a concentration of 0.1  mg/ml while the highest 
concentration of hyaluronic acid (1  mg/ml) caused an 
inhibition of adherence of S. suis to BMEC. More specifi-
cally, adherence of S. suis P1/7 decreased by 68 %.
The effect of hyaluronic acid on gene expression of five 
virulence-associated markers (capsule [cps2J], extracel-
lular protein factor [epf], muraminidase-released protein 
[mrp], suilysin [sly] and DNase [ssnA]) in S. suis P1/7 
was determined by RT-qPCR using 16S rRNA as ref-
erence gene. Hyaluronic acid at 0.625 and 1.25  mg/ml 
increased cps expression by a factor 1.3 and 1.8, respec-
tively (Fig.  5a). An increase in epf expression was also 
observed in the presence of hyaluronic acid (Fig. 5b); the 
highest increase (1.65-fold) was observed with 1.25 mg/
ml of hyaluronic acid. In the presence of  ≤  2.5  mg/ml 
hyaluronic acid, the expression of mrp increased, reach-
ing a maximum of 2-fold increase at 1.25 mg/ml (Fig. 5c). 
The expression of sly was 1.6- and 1.7-fold higher in the 
presence of 1.25 and 2.5 mg/ml hyaluronic acid, respec-
tively, compared to control (Fig.  5d). Lastly, the expres-
sion of ssnA was 1.5- and 1.7-fold higher in the presence 
of hyaluronic acid at 0.625 and 1.25  mg/ml hyaluronic 
acid, respectively (Fig. 5e).
Effect of hyaluronic acid on pro‑inflammatory cytokine 
secretion by BMEC
BMEC were treated with hyaluronic acid (18  h) at con-
centrations ranging from 0.1 to 2 mg/ml prior to deter-
mine pro-inflammatory cytokine (IL-6, CXCL-8, IL-1β 
and TNF-α) secretion by ELISA. While no production of 
IL-1β and TNF-α was observed (data not shown), levels 
of IL-6 and CXCL-8 increased in a dose-dependent fash-
ion as reported in Fig.  6a, b, respectively. More specifi-
cally, when hyaluronic acid was added at 2  mg/ml, IL-6 
and CXCL-8 secretion was 3.6 and 12.8 times higher than 
the control, respectively.
Discussion
In 2004, a hyaluronate lyase (130 kDa) produced by the 
swine pathogen S. suis (serotype 7) has been identified 
and proposed as a virulence factor [18]. The fact that 
not all virulent strains expressed an active form of the 
enzyme suggested that S. suis hyaluronate lyase should 
not be considered as an essential virulence factor [24]. 
In this study, we focused on strains of S. suis serotype 2, 
which represents the most commonly isolated serotype 
from sick animals. In order to further investigate the rela-
tionship between expression of active hyaluronate lyase 
and virulence, we used S. suis serotype 2 strains belong-
ing to the three clonal complexes present in North Amer-
ica, known as ST1, ST25 and ST28. It has been previously 
reported that these STs differ in their degree of virulence 
in a mouse infection model, ST1 isolates possess a high 
virulence whereas ST25 and ST28 isolates have an inter-
mediate and low virulence, respectively [8]. While all 
ST25 and ST28 strains possessed hyaluronate lyase activ-
ity, sixteen out of seventeen isolates belonging to ST1 
were devoid of activity. Interestingly, the only ST1 isolate 
positive for hyaluronate lyase activity (S. suis S735) has 
been previously reported to be only weakly virulent in 
piglets [33]. From the above data, an inverse correlation 
between virulence and the presence of hyaluronate lyase 
activity can be suggested.
Genetic analysis of the hyaluronate lyase gene of ST1, 
ST25 and ST28 strains showed the presence of four 
conserved insertions in strains belonging to ST1. The 
2  bp insertion at position 1554–1555 is responsible for 
a shifted reading frame leading to an early stop codon 
resulting in a truncated form of the hyaluronate lyase in 
ST1 isolates, thus explaining the lack of hyaluronate lyase 
activity in these strains. Interestingly, it has been shown 
that this truncated protein (53 kDa) was able to interact 
with an angiogenin inhibitor [25]. Such an interaction 
could inactivate the angiogenin inhibitor, thus promoting 
angiogenesis and vascular permeability that could allow 
S. suis to cross the blood–brain barrier and cause men-
ingitis. It can be speculated that the loss of hyaluronate 
lyase activity in the most virulent strains of S. suis could 
have resulted in an increased bacterial virulence through 
such a mechanism.
Given that S. suis ST1 strains that do not produce 
active hyaluronate lyase are likely to interact with host 
hyaluronic acid in  vivo, we then investigated the effects 
of this glycosaminoglycan on some biological proper-
ties of S. suis P1/7, a reference ST1 strain. Since the 
hyaluronic acid-rich capsule of S. pyogenes has been 
described as important for biofilm formation, as it could 
be involved in intercellular adherence between bacteria 
[34], we evaluated whether supplementing the culture 
medium with exogenous hyaluronic acid could induce 
Fig. 4 Effect of hyaluronic acid on the adherence of S. suis P1/7 to 
BMEC. *Significantly different from control at p < 0.05
Page 8 of 11Haas et al. BMC Res Notes  (2015) 8:722 
biofilm formation by S. suis, for which most strains can-
not form a biofilm in a basal culture medium [35]. Our 
data revealed that hyaluronic acid at low concentration 
(0.05 mg/ml) reduced biofilm formation whereas higher 
concentrations (0.1 and 0.5  mg/ml) stimulated biofilm 
formation. These observations suggest that at a concen-
tration of 0.05  mg/ml, hyaluronic acid could interfere 
with intercellular adhesion of S. suis or exopolysaccha-
ride secretion. It was also found that high concentration 
of hyaluronic acid (1 mg/ml) inhibits the ability of S. suis 
to grow and produce a biofilm, probably due to the high 
osmotic pressure created.
It has been reported that at the early step of the path-
ogenic process of meningitis, S. suis adheres to BMEC 
Fig. 5 Effect of hyaluronic acid on virulence factor gene expression by S. suis P1/7. Relative gene expression of cps2J (a), epf (b), mrp (c), sly (d), ssnA 
(e). Significantly different from control at #p < 0.05; *p < 0.01
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in order to facilitate migration of bacteria through the 
blood–brain barrier [36]. In this regard, we then evalu-
ated the effect of exogenous hyaluronic acid on the 
adherence of S. suis P1/7 (ST1) to BMEC. In the presence 
of hyaluronic acid at a low concentration (0.1  mg/ml), 
bacterial adherence was increased, while at a high con-
centration (1 mg/ml), the adherence of S. suis to BMEC 
was significantly decreased. Using FITC-labeled hyalu-
ronic acid, it was found that hyaluronic acid preferentially 
binds to BMEC and not to bacteria (Additional file 1: Fig-
ure S1). From the above observations, it may be suggested 
that at high concentrations, binding of hyaluronic acid to 
BMEC could lead to a decreased accessibility of recep-
tors for S. suis, resulting in a lower bacterial adherence to 
BMEC. However, at low concentrations, the cell surface 
charge of the BMEC may be modified by hyaluronic acid, 
resulting in increased bacterial adherence. Interestingly, 
hyaluronic acid has been previously reported to modu-
late the adherence of Mycobacterium tuberculosis to lung 
epithelium [37]. Our results are thus in agreement with 
these previous observations, especially that hyaluronic 
acid at high concentrations inhibits bacterial adherence. 
However, the molecular mechanisms of S. suis adher-
ence to cells via exogenous hyaluronic acid remains to be 
characterized.
It has been shown that growing S. pyogenes in the pres-
ence of hyaluronic acid resulted in an increased expres-
sion of several virulence factors, including the M1 protein 
and a collagen-like surface protein, that play key roles in 
the pathogenesis of GAS infections [38]. Growing S. suis 
P1/7 in hyaluronic acid-supplemented culture medium 
was found to increase the expression of several virulence-
associated markers such as the cell wall-anchored DNase, 
suilysin, MRP, EPF and capsule. Consequently, it can be 
hypothesized that the virulence of S. suis can be modu-
lated by the presence of hyaluronic acid under in  vivo 
conditions. Given the fact that S. suis P1/7 does not 
express an active form of hyaluronate lyase, the changes 
observed in virulence-associated markers gene expres-
sion can be linked with an adaptation to an osmotic or 
acidic stress in the culture medium supplemented with 
hyaluronic acid.
Hyaluronic acid from the host is likely to be present 
during infections caused by S. suis ST1 isolates, con-
sidering that they do not produce an active hyaluronate 
lyase. Hyaluronic acid has been reported to possess 
pro- and anti-inflammatory properties depending on 
the size of the molecule [28]. In our study, stimulation of 
BMEC with hyaluronic acid was associated with a pro-
inflammatory effect. More specifically, hyaluronic acid 
was found to dose-dependently increase the secretion of 
IL-6 and CXCL-8, two major inflammatory mediators. 
In a previous study, it has been reported that hyaluronic 
acid can modulate pro-inflammatory cytokines secre-
tion in human uterine fibroblasts by interacting with the 
CD44 receptor [39]. Our observations suggest a lower 
inflammatory potential for strains possessing an active 
hyaluronate lyase. Indeed, these isolates could degrade 
hyaluronic acid in the extracellular matrix thus decreas-
ing pro-inflammatory cytokines secretion by host cells.
Conclusions
Our study brought evidence that hyaluronate lyase in its 
full length and active form does not represent a key viru-
lence factor for S. suis. Indeed, hyaluronate lyase appears 
to be active only in isolates of S. suis serotype 2 belong-
ing to the less virulent STs (ST25 and ST28). Consider-
ing that the S. suis P1/7 hyaluronate lyase (truncated and 
inactive form) has been shown to interact with an angi-
ogenin inhibitor [25], it can be suggested that the highly 
conserved 2  bp insertion in the hyaluronate lyase gene 
could lead to more invasive isolates by enhancing vascu-
lar permeability of the blood–brain barrier leading to the 
development of meningitis. Since Wu et  al. [25] mainly 
focused their study on the truncated form of hyaluronate 
Fig. 6 Effect of hyaluronic acid on the secretion of IL-6 (a) and IL-8 
(CXCL-8) (b) by BMEC. *Significantly different from control at p < 0.05
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lyase, no data are available on the interaction of the active 
form of hyaluronate lyase with the angiogenin inhibitor, 
a phenomenon that may be important in the endothe-
lial dysregulation associated with meningitis. Given that 
strains of S. suis belonging to ST1, the most virulent ST, 
do not degrade hyaluronic acid, we investigated the effect 
of this glycosaminoglycan on S. suis and host cells. While 
hyaluronic acid did not promote biofilm formation, it was 
found to modulate S. suis adhesion to BMEC. Moreover, 
hyaluronic acid increased virulence factor gene expres-
sion in S. suis and enhanced pro-inflammatory cytokine 
secretion by BMEC.
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